Biological: HX15001
Phase 1
Biological: HX15001 is one of 7 therapeutic programs targeting Colitis, Ulcerative. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
8 competitors in Colitis, Ulcerative
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonPhase 3
Omvoh
Eli LillyPhase 2
Velsipity
PfizerPhase 2
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Zeposia
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Aletekitug
GSKPhase 1
Biological: HX15001
HHelixon Biotechnology (Suzhou) Co., Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Biological: HX15001. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]